Fresenius Medical Care (NYSE:FMS) Releases Earnings Results, Beats Estimates By $0.07 EPS

Fresenius Medical Care (NYSE:FMS - Get Free Report) announced its earnings results on Tuesday. The company reported $0.48 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.41 by $0.07, Zacks reports. Fresenius Medical Care had a return on equity of 6.04% and a net margin of 3.43%.

Fresenius Medical Care Stock Up 0.7 %

NYSE:FMS traded up $0.15 on Tuesday, hitting $23.46. 203,911 shares of the company's stock traded hands, compared to its average volume of 248,286. The company has a market cap of $13.77 billion, a PE ratio of 19.39, a price-to-earnings-growth ratio of 0.76 and a beta of 0.93. Fresenius Medical Care has a 1 year low of $17.93 and a 1 year high of $25.25. The company has a current ratio of 1.37, a quick ratio of 1.02 and a debt-to-equity ratio of 0.42. The firm has a 50-day moving average price of $23.39 and a 200-day moving average price of $21.77.

Analyst Ratings Changes

Several analysts have issued reports on the company. StockNews.com upgraded Fresenius Medical Care from a "hold" rating to a "strong-buy" rating in a report on Wednesday, February 5th. Berenberg Bank started coverage on shares of Fresenius Medical Care in a report on Wednesday, November 6th. They set a "buy" rating and a $25.60 price target on the stock. Bank of America raised shares of Fresenius Medical Care from an "underperform" rating to a "neutral" rating in a research note on Monday, December 2nd. Finally, Truist Financial boosted their target price on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the company a "hold" rating in a research note on Monday, January 6th.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.